FDA approves new, cheaper rival to EpiPen allergy shot
Share
Tweet
June 16, 2017
U.S. regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical greed.
The Food and Drug Administration on Thursday approved Adamis (ad-DEHM-iss) Pharmaceuticals Corp.'s product, which should go on sale later this year.
Symjepi (sim-JEPP'-ee) is a syringe prefilled with the hormone epinephrine, which helps stop life-threatening allergic reactions from insect stings and bites or eating foods such as nuts and eggs.
San Diego-based Adamis says its product is easier to use than Mylan's EpiPen, an autoinjector that comes wit...
For access to this article please
sign in or
subscribe.
Reader Comments(0)